BIOMARIN PHARMACEUTICAL INC executive Gregory R. Friberg, EVP and Chief R&D Officer, reported an open-market sale of 6,326 shares of common stock on February 26, 2026. The shares were sold at a weighted average price of $60.3758 per share, with individual sale prices ranging from $60.36 to $60.51 according to the footnote. After this transaction, Friberg directly holds 37,578 shares of BioMarin common stock.
BioMarin Pharmaceutical EVP and Chief Legal Officer George Eric Davis reported both stock sales and equity awards. On February 26, 2026, he completed an open-market sale of 26,061 shares of common stock at $61.36 per share, leaving 72,453 shares held directly afterward.
On February 25, 2026, he acquired three blocks of common stock through grants or awards totaling 15,224 earned restricted stock units (RSUs), all at a stated price of $0.00 per share. These RSUs were earned under performance-based awards tied to relative total shareholder return, development goals, and core operating margin for 2023–2025, and will vest on March 15, 2026 subject to continued service and certain earlier-vesting events.
BioMarin Pharmaceutical executive Brian Mueller received multiple performance-based stock awards. On February 25, 2026, he acquired 6,683, 7,230, and 2,569 shares of common stock at $0 per share through grants classified as awards, not open-market purchases.
These shares come from Restricted Stock Units earned for performance over 2023–2025, based on relative total shareholder return, development goals, and core operating margin. The earned RSUs convert into common stock on a 1:1 basis and are scheduled to vest on March 15, 2026, subject to his continued service, with earlier vesting possible upon certain events. Following these awards, he directly owns 116,638 common shares.
BioMarin Pharmaceutical Inc. notice of proposed sale of common stock on a Form 144 through a broker-dealer. The filing lists Fidelity Brokerage Services LLC and references proposed transactions tied to restricted stock vesting on 09/30/2025 (5928 shares) and an ESPP purchase on 10/31/2025 (398 shares). The form records the broker and an entry date of 02/26/2026.
BioMarin Pharmaceutical reports 2025 total revenues of $3.2 billion, driven largely by growth in VOXZOGO and its enzyme therapy franchise. VOXZOGO generated $926.9 million in 2025 net product revenue, while enzyme therapies and other rare-disease drugs added diversified sales.
The company agreed in December 2025 to acquire Amicus Therapeutics for $4.8 billion in cash, funded by cash on hand, $850.0 million of 5.5% senior notes due 2034, and an expected $2.8 billion term loan plus a $600.0 million revolving credit facility. BioMarin plans to expand its portfolio with Fabry and late‑onset Pompe disease therapies.
BioMarin is exiting ROCTAVIAN after lower‑than‑anticipated commercial opportunities, recording about $240.0 million in 2025 restructuring charges for inventory write‑offs, asset impairments, and severance. As of February 19, 2026, it had 192,323,359 shares of common stock outstanding and continues advancing a robust pipeline, including BMN 333, BMN 351, and BMN 401.
BioMarin Pharmaceutical (BMRN) filed a Form 144 reporting a proposed sale of common stock by Fidelity Brokerage Services LLC. The notice lists multiple lots tied to prior acquisitions, including 1,474 shares from a stock option exercise (02/24/2023), 317 shares from an ESPP purchase (04/30/2023), 301 shares from an ESPP purchase (04/30/2024), and 23,969 shares from restricted stock vesting (03/15/2025).
BioMarin Pharmaceutical reported strong growth for 2025 and set higher profit goals for 2026 while reshaping its portfolio. Total revenues rose 13% to $3.221 billion, with fourth quarter revenues up 17% to $875 million. Growth was led by VOXZOGO, which delivered 26% full‑year revenue growth to $927 million, and Enzyme Therapies, up 9% to $2.105 billion.
Full‑year GAAP net income was $348.9 million and Non‑GAAP Income was $614 million, equal to Non‑GAAP diluted EPS of $3.15. Fourth quarter GAAP results showed a $47 million net loss due to approximately $240 million of charges tied to voluntarily withdrawing ROCTAVIAN from the market. Non‑GAAP income for the quarter was $89 million.
BioMarin announced a definitive agreement to acquire Amicus Therapeutics, adding Galafold and Pombiliti + Opfolda, and has secured about $3.7 billion of non‑convertible debt financing. For 2026, excluding any post‑close Amicus contribution, the company guides to total revenues of $3.325–$3.425 billion and Non‑GAAP diluted EPS of $4.95–$5.15, with an expected Non‑GAAP operating margin of about 40%.
BioMarin Pharmaceutical Inc. has closed a private offering of $850 million in 5.500% senior unsecured notes due 2034. The issue price was 100.000%, and the notes were sold to qualified institutional buyers and certain non-U.S. investors.
BioMarin plans to use the net proceeds, together with a new $2 billion senior secured term loan B facility, a $800 million term loan A facility and cash on hand, to fund the pending acquisition of Amicus Therapeutics, Inc. and related fees and expenses. It also expects to enter into a $600 million senior secured revolving credit facility and may borrow up to $150 million under it for transaction costs.
Offering proceeds are held in escrow until the Amicus acquisition closes. If the deal is not completed on or before December 19, 2026, or certain other events occur, BioMarin must redeem the notes at 100% of the initial issue price plus accrued interest. The notes are guaranteed by certain subsidiaries and are subject to covenants limiting additional debt, dividends, liens, asset sales and mergers.
BioMarin Pharmaceutical Inc. is raising debt financing to help fund its pending acquisition of Amicus Therapeutics. The company agreed to sell $850 million of 5.500% senior unsecured notes due 2034 in a private offering to qualified institutional buyers and non‑U.S. persons.
BioMarin also completed syndication of a new $2 billion senior secured term loan B facility, in addition to a previously arranged $800 million senior secured term loan A facility, and expects to enter into a $600 million senior secured revolving credit facility. It plans to use net proceeds from the notes, together with borrowings under the term facilities and cash on hand, to pay the Acquisition consideration and related fees and expenses. If the Acquisition is not completed by December 19, 2026, BioMarin must redeem the notes at 100% of their initial issue price plus accrued interest.
BioMarin Pharmaceutical Inc. estimates that it generated approximately $3.2 billion in total revenues (unaudited) for the year ended December 31, 2025, including about $920 million from sales of VOXZOGO®. As of December 31, 2025, it reports approximately $2.1 billion in cash, cash equivalents and investments, all on a preliminary, unaudited basis.
The company also announces plans to offer $850 million of senior unsecured notes due 2034 in a private placement and to arrange a $2 billion Term Loan B facility, a $800 million Term Loan A facility, and a $600 million new revolving credit facility. Together with potential borrowings of up to $150 million under the revolver, these financings are intended to fund the pending acquisition of Amicus Therapeutics, Inc. and related costs. BioMarin is providing supplemental risk factors and unaudited pro forma combined financial information to illustrate the impact of the acquisition and financing.